5H-Benzo[d]naphth[2,1-b]azepin-12-ol, 11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-, hydrobromide (1:1), (6aS,13bR)-

Product Name5H-Benzo[d]naphth[2,1-b]azepin-12-ol, 11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-, hydrobromide (1:1), (6aS,13bR)-
CAS2587360-22-1
MFC19H21BrClNO
MW394.74
EINECS
MOL File2587360-22-1.mol

Chemical Properties

form	Solid
color	White to off-white

Usage And Synthesis

Uses

Ecopipam (SCH 39166) hydrobromide is a potent, selective and orally active antagonist of dopamine D1/D5 receptor, with Kis of 1.2 nM and 2.0 nM, respectively. Ecopipam hydrobromide shows more than 40-flod selectivity over D2, D4, 5-HT, and α2a receptor (Ki=0.98, 5.52, 0.08, and 0.73 μM, respectively). Ecopipam hydrobromide can be used for the research of schizophrenia and obesity[1].

in vivo

Ecopipam (10, mg/kg, oral administration) antagonizes Apomorphine-induced stereotypy in rats^[4].
Ecopipam (5 and 10 μM, perfusion, 1 μL/min) reversibly and dose-dependently decreases acetylcholine release in the rat striatum^[5].

Animal Model:	Male young adult Long-Evans rats were injected with Nicotine^[3]
Dosage:	0.003, 0.01, 0.03, 0.1, 0.3 mg/kg
Administration:	A single s.c. 20 min before Nicotine (0.1 mg/kg)
Result:	Dose-dependently reduced pressing on both active and inactive levers.

IC 50

D₁ Receptor: 1.2 nM (Ki); D₅ Receptor: 2.0 nM (Ki); D₂ Receptor: 980 nM (Ki); D₄ Receptor: 5520 nM (Ki); 5-HT Receptor: 80 nM (Ki); Alpha-2A adrenergic receptor: 731 nM (Ki)

References

[1] Wu WL, et al. Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists. J Med Chem. 2005 Feb 10;48(3):680-93. DOI:10.1021/jm030614p
[2] Sharopov S, et al. Dopaminergic modulation of low-Mg2?-induced epileptiform activity in the intact hippocampus of the newborn mouse in vitro. J Neurosci Res. 2012 Oct;90(10):2020-33. DOI:10.1002/jnr.23084
[3] Satanove DJ, et al. Nicotine-induced enhancement of a sensory reinforcer in adult rats: antagonist pretreatment effects. Psychopharmacology (Berl). 2021 Feb;238(2):475-486. DOI:10.1007/s00213-020-05696-5
[4] R E Chipkin, et al. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. J Pharmacol Exp Ther. 1988 Dec;247(3):1093-102. PMID:2905002
[5] E Acquas, et al. Local application of SCH 39166 reversibly and dose-dependently decreases acetylcholine release in the rat striatum. Eur J Pharmacol. 1999 Nov 3;383(3):275-9. DOI:10.1016/s0014-2999(99)00660-3

5H-Benzo[d]naphth[2,1-b]azepin-12-ol, 11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-, hydrobromide (1:1), (6aS,13bR)- Supplier

Send Inquriy